07/12/2018 17:53:26

ImmusanT Chief Scientific Officer Robert Anderson, Ph.D. to Participate as a Featured Speaker During the Antigen-Specific Immune Tolerance Europe Conference 2018

CAMBRIDGE, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, announced today that Robert (Bob) Anderson, Ph.D., will be among the featured speakers during the Antigen-Specific Immune Tolerance Europe Conference 2018 in London from Dec. 10-12, 2018.

“I am delighted to have been invited to participate as a featured speaker during this conference,” said Dr. Anderson. “We have made significant strides in the discovery and development of immune tolerizing therapeutics that have the potential to transform how we treat patients with autoimmune disorders. I look forward to sharing my insights with other experts in the field.” 

The conference is the first, European centric platform that brings together key decision makers to discuss the translation of groundbreaking science into novel therapies that address significant unmet needs in a variety of autoimmune disorders.

About ImmusanT, Inc.

At ImmusanT, we are developing a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Our Epitope-Specific Immuno-Therapy™ (ESIT™) platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. Our lead program, Nexvax2®, is in clinical development with the goal of protecting celiac disease patients against the debilitating effects of gluten. www.ImmusanT.com 

Media Contact:

Andrew Mielach

Account Supervisor

LifeSci Public Relations

(646) 876-5868

amielach@lifescipublicrelations.com  

 

immusanT_logo_031111.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Aug
VELO
Da flere skribenter stadig gerne vil beholde tråden for samling af de mange vigtige informationer o..
44
15 Aug
VELO
Det kunne tyde på at nogen mor modtaget receptal, der udviser netop det vi har talt om - at Envarsus..
37
19 Aug
OMXC25
Endnu en dansk patriark er død. Ære være hans minde.
28
18 Aug
 
Da Berlingske Media for cirka 1 år siden overtog Euroinvestor for 23 mio kr, meddelte de, at nu skul..
22
18 Aug
VELO
Fra anden skribent i Veloxis FB gruppen: Børsen side 4, søndag den 18. august. Et uddrag fra e..
20
20 Aug
VELO
Ny artikel på Medwatch:   15,5 pct. af amerikanske patienter, der får en nyretransplantation i dag, ..
19
20 Aug
PNDORA
  har du læst regnskabet - de forventer at tjene 4 mia i 2019 i forhold til en værdi af selskabet på..
17
19 Aug
OMXC25
En fantastisk dygtig og sympatisk erhvervsmand.  Og en ægte patriot som også betalte sin skat med gl..
17
16 Aug
I:NDX
17
14 Aug
TEVA
Ja, TEVA er jo bare en dårlig historie at købe ind i. I Danmark er aktien (som alle jo ved) primært ..
16

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Industry Welcomes Second-Generation Low Emission Methanol-Fuelled Vessels
2
CADE INVESTIGATION UPDATE: Hagens Berman Reminds Cadence Bancorp. (CADE) Investors of Ongoing Investigation
3
GDOT INVESTOR ALERT: Hagens Berman Investigating Possible Disclosure Violations by Green Dot Corporation (GDOT), Encourages Investors Who Lost $50,000+ to Contact the Firm
4
CARB Investor Alert: Hagens Berman Reminds Carbonite, Inc. (CARB) Investors of September 30, 2019 Lead Plaintiff Deadline
5
True Nature Holding Announces A Private Offering Under Rule 506(C) Of Its New Series A, 10% Cumulative Redeemable Perpetual Preferred Stock Offering

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 August 2019 11:03:28
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB7 - 2019-08-21 12:03:28 - 2019-08-21 11:03:28 - 1000 - Website: OKAY